Genomic profiling in luminal breast cancer

Oleg Gluz; Daniel Hofmann; Rachel Würstlein; Cornelia Liedtke; Ulrike Nitz; Nadia Harbeck

doi:10.1159/000357535

Genomic profiling in luminal breast cancer

Oleg Gluz^*, Daniel Hofmann, Rachel Würstlein, Cornelia Liedtke, Ulrike Nitz, Nadia Harbeck

^*Corresponding author for this work

Department of Gynecology and Obstetrics

11 Citations (Scopus)

Abstract

SummaryThe developments in gene expression analysis have made it possible to sub-classify hormone receptor-positive (luminal) breast cancer in different prognostic subgroups. This sub-classification is currently used in clinical routine as prognostic signature (e.g. 21-gene Onoctype DX®, 70-gene Mammaprint®). As yet, the optimal method for sub-classification has not been defined. Moreover, there is no evidence from prospective trials. This review explores widely used genomic signatures in luminal breast cancer, making a critical appraisal of evidence from retrospective/prospective trials. It is based on systematic literature search performed using Medline (accessed September 2013) and abstracts presented at the Annual Meeting of American Society of Clinical Oncology and San Antonio Breast Cancer Symposium.

Original language	English
Journal	Breast Care
Volume	8
Issue number	6
Pages (from-to)	414-422
Number of pages	9
ISSN	1661-3791
DOIs	https://doi.org/10.1159/000357535
Publication status	Published - 01.12.2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1159/000357535

Cite this

@article{a77f1e4cf9f64e7294e5928fee43fcfb,

title = "Genomic profiling in luminal breast cancer",

abstract = "SummaryThe developments in gene expression analysis have made it possible to sub-classify hormone receptor-positive (luminal) breast cancer in different prognostic subgroups. This sub-classification is currently used in clinical routine as prognostic signature (e.g. 21-gene Onoctype DX{\textregistered}, 70-gene Mammaprint{\textregistered}). As yet, the optimal method for sub-classification has not been defined. Moreover, there is no evidence from prospective trials. This review explores widely used genomic signatures in luminal breast cancer, making a critical appraisal of evidence from retrospective/prospective trials. It is based on systematic literature search performed using Medline (accessed September 2013) and abstracts presented at the Annual Meeting of American Society of Clinical Oncology and San Antonio Breast Cancer Symposium.",

author = "Oleg Gluz and Daniel Hofmann and Rachel W{\"u}rstlein and Cornelia Liedtke and Ulrike Nitz and Nadia Harbeck",

year = "2013",

month = dec,

day = "1",

doi = "10.1159/000357535",

language = "English",

volume = "8",

pages = "414--422",

journal = "Breast Care",

issn = "1661-3791",

publisher = "S. Karger AG",

number = "6",

}

TY - JOUR

T1 - Genomic profiling in luminal breast cancer

AU - Gluz, Oleg

AU - Hofmann, Daniel

AU - Würstlein, Rachel

AU - Liedtke, Cornelia

AU - Nitz, Ulrike

AU - Harbeck, Nadia

PY - 2013/12/1

Y1 - 2013/12/1

N2 - SummaryThe developments in gene expression analysis have made it possible to sub-classify hormone receptor-positive (luminal) breast cancer in different prognostic subgroups. This sub-classification is currently used in clinical routine as prognostic signature (e.g. 21-gene Onoctype DX®, 70-gene Mammaprint®). As yet, the optimal method for sub-classification has not been defined. Moreover, there is no evidence from prospective trials. This review explores widely used genomic signatures in luminal breast cancer, making a critical appraisal of evidence from retrospective/prospective trials. It is based on systematic literature search performed using Medline (accessed September 2013) and abstracts presented at the Annual Meeting of American Society of Clinical Oncology and San Antonio Breast Cancer Symposium.

AB - SummaryThe developments in gene expression analysis have made it possible to sub-classify hormone receptor-positive (luminal) breast cancer in different prognostic subgroups. This sub-classification is currently used in clinical routine as prognostic signature (e.g. 21-gene Onoctype DX®, 70-gene Mammaprint®). As yet, the optimal method for sub-classification has not been defined. Moreover, there is no evidence from prospective trials. This review explores widely used genomic signatures in luminal breast cancer, making a critical appraisal of evidence from retrospective/prospective trials. It is based on systematic literature search performed using Medline (accessed September 2013) and abstracts presented at the Annual Meeting of American Society of Clinical Oncology and San Antonio Breast Cancer Symposium.

UR - https://www.scopus.com/pages/publications/84892414644

U2 - 10.1159/000357535

DO - 10.1159/000357535

M3 - Scientific review articles

AN - SCOPUS:84892414644

SN - 1661-3791

VL - 8

SP - 414

EP - 422

JO - Breast Care

JF - Breast Care

IS - 6

ER -

Genomic profiling in luminal breast cancer

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this